Impact of previous biologic use and body weight on the effectiveness of guselkumab in moderate-to-severe plaque psoriasis: a real-world practice
YT Hung, YJ Lin, HY Chiu… - Therapeutic Advances in …, 2021 - journals.sagepub.com
Background: Real-life data on patients with psoriasis treated with guselkumab are few and
are needed to compare with trial-based data. We investigated the effect of clinical factors on …
are needed to compare with trial-based data. We investigated the effect of clinical factors on …
Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real …
C Lynde, E Riedl, JT Maul, T Torres, A Pinter… - Advances in …, 2023 - Springer
Introduction In routine clinical care, important treatment outcomes among patients with
moderate-to-severe plaque psoriasis (PsO) have been shown to vary according to patient …
moderate-to-severe plaque psoriasis (PsO) have been shown to vary according to patient …
Choosing the right biologic for complications of inflammatory bowel disease
S Rakowsky, K Papamichael… - Expert Review of …, 2022 - Taylor & Francis
Introduction Inflammatory bowel disease (IBD) is a chronic, inflammatory condition that
involves the intestinal tract, and can also present with extra-intestinal manifestations (EIM) …
involves the intestinal tract, and can also present with extra-intestinal manifestations (EIM) …
Response to Biologic Therapy in Skin of Colour Participants With Moderate-to-Severe Psoriasis and Atopic Dermatitis: A Systematic Review
H Rijal, N Bouadi, A Abduelmula… - Journal of …, 2024 - journals.sagepub.com
There has been a call to action to enhance representation of non-white individuals in
dermatology clinical trials. Investigations in differential response to treatment across …
dermatology clinical trials. Investigations in differential response to treatment across …
Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study
NRM Alves, PS Kurizky, LMH Mota… - Anais Brasileiros de …, 2024 - SciELO Brasil
Background: Real-world, primary data on the treatment of psoriasis are scarce, especially
concerning the role of soluble biomarkers as outcome predictors. Objective: The authors …
concerning the role of soluble biomarkers as outcome predictors. Objective: The authors …
Efficacy, safety, and pharmacoeconomic analysis of adalimumab and secukinumab for moderate-to-severe plaque psoriasis: a single-center, real-world study
G Li, Y Gu, Q Zou, Y Wang, Y Xiao, D Xia, T Zhan… - Dermatology and …, 2022 - Springer
Introduction A growing number of biologics have recently been approved in China for
psoriasis treatment, and some of these are eligible for Chinese medical insurance, resulting …
psoriasis treatment, and some of these are eligible for Chinese medical insurance, resulting …
[HTML][HTML] Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan
Background: Psoriasis is a chronic inflammatory disease involving the skin and/or joints. Till
2016, there were five biologic agents for psoriatic arthritis treatment in Taiwan: etanercept …
2016, there were five biologic agents for psoriatic arthritis treatment in Taiwan: etanercept …
Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis
J Ma, J Cai, H Chen, Z Feng, G Yang - Journal of Atherosclerosis and …, 2024 - jstage.jst.go.jp
Aim: Evidence regarding the association between various tumor necrosis factor-α (TNF-α)
inhibitors and cardiovascular adverse events (AEs) is both limited and contradictory …
inhibitors and cardiovascular adverse events (AEs) is both limited and contradictory …
[PDF][PDF] Terapia biológica no tratamento da psoríase moderada a grave: revisão sistemática Biological therapy in the treatment of moderate to severe psoriasis …
CF Jacquiminut, GM Azevedo… - Brazilian Journal of …, 2021 - scholar.archive.org
RESUMO INTRODUÇÃO: A Psoríase é uma doença inflamatória crônica que acomete
principalmente a pele e as articulações. Em pacientes com psoríase moderada ou grave …
principalmente a pele e as articulações. Em pacientes com psoríase moderada ou grave …
On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study
P Sermsaksasithorn, C Wongtada… - Journal of …, 2022 - Taylor & Francis
Background Off-label uses of biologics in the treatment of psoriasis are usually implemented
in limited-resource settings and studies regarding their response profiles are limited. Method …
in limited-resource settings and studies regarding their response profiles are limited. Method …